BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Young AM, Crosby RA, Oser CB, Leukefeld CG, Stephens DB, Havens JR. Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia. J Med Virol 2012;84:1376-87. [PMID: 22825816 DOI: 10.1002/jmv.23252] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Stephens DB, Havens JR. Predictors of alcohol use among rural drug users after disclosure of hepatitis C virus status. J Stud Alcohol Drugs 2013;74:386-95. [PMID: 23490567 DOI: 10.15288/jsad.2013.74.386] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
2 Grassi E, Aghemo A. How to optimize HCV therapy in genotype 2 patients. Liver Int. 2013;33 Suppl 1:35-40. [PMID: 23286844 DOI: 10.1111/liv.12056] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
3 Hofmeister MG, Havens JR, Young AM. Silence Surrounding Hepatitis C Status in Risk Relationships Among Rural People Who Use Drugs. J Prim Prev 2017;38:481-94. [PMID: 28733798 DOI: 10.1007/s10935-017-0483-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
4 Marciano S, Gadano AC. How to optimize current treatment of genotype 2 hepatitis C virus infection. Liver Int 2014;34:13-7. [DOI: 10.1111/liv.12399] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
5 Novack LM, Carrasco KG, Tyler KA, Dombrowski K, Habecker P. Injection Opioid and Injection Methamphetamine Use in the Rural United States: A Systematic Review and Network Analysis. Journal of Drug Issues 2020;50:127-41. [DOI: 10.1177/0022042619895247] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Young AM, Jonas AB, Havens JR. Social networks and HCV viraemia in anti-HCV-positive rural drug users. Epidemiol Infect 2013;141:402-11. [PMID: 22717190 DOI: 10.1017/S0950268812000696] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
7 Daw MA, El-Bouzedi A, Dau AA. Geographic distribution of HCV genotypes in Libya and analysis of risk factors involved in their transmission. BMC Res Notes. 2015;8:367. [PMID: 26293137 DOI: 10.1186/s13104-015-1310-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
8 Ibragimov U, Cooper KE, Batty E, Ballard AM, Fadanelli M, Gross SB, Klein EM, Lockard S, Young AM, Cooper HLF. Factors that influence enrollment in syringe services programs in rural areas: a qualitative study among program clients in Appalachian Kentucky. Harm Reduct J 2021;18:68. [PMID: 34193165 DOI: 10.1186/s12954-021-00518-z] [Reference Citation Analysis]
9 Havens JR, Schaninger T, Fraser H, Lofwall M, Staton M, Young AM, Hoven A, Walsh SL, Vickerman P. Eliminating hepatitis C in a rural Appalachian county: protocol for the Kentucky Viral Hepatitis Treatment Study (KeY Treat), a phase IV, single-arm, open-label trial of sofosbuvir/velpatasvir for the treatment of hepatitis C. BMJ Open 2021;11:e041490. [PMID: 34226208 DOI: 10.1136/bmjopen-2020-041490] [Reference Citation Analysis]
10 Beal EW, Tumin D, Sobotka L, Tobias JD, Hayes D Jr, Pawlik TM, Washburn K, Mumtaz K, Conteh L, Black SM. Patients From Appalachia Have Reduced Access to Liver Transplantation After Wait-Listing. Prog Transplant 2018;28:305-13. [PMID: 30205758 DOI: 10.1177/1526924818800037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Goolsby Hunter A, Rosenblatt L, Patel C, Blauer-Peterson C, Anduze-Faris B. Clinical characteristics, healthcare costs, and resource utilization in hepatitis C vary by genotype. Curr Med Res Opin 2017;33:829-36. [PMID: 28128648 DOI: 10.1080/03007995.2017.1288613] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
12 Suryaprasad AG, White JZ, Xu F, Eichler B, Hamilton J, Patel A, Hamdounia SB, Church DR, Barton K, Fisher C, Macomber K, Stanley M, Guilfoyle SM, Sweet K, Liu S, Iqbal K, Tohme R, Sharapov U, Kupronis BA, Ward JW, Holmberg SD. Emerging Epidemic of Hepatitis C Virus Infections Among Young Nonurban Persons Who Inject Drugs in the United States, 2006–2012. Clinical Infectious Diseases 2014;59:1411-9. [DOI: 10.1093/cid/ciu643] [Cited by in Crossref: 343] [Cited by in F6Publishing: 312] [Article Influence: 42.9] [Reference Citation Analysis]
13 Iqbal K, Klevens RM, Kainer MA, Baumgartner J, Gerard K, Poissant T, Sweet K, Vonderwahl C, Knickerbocker T, Khudyakov Y. Epidemiology of Acute Hepatitis B in the United States From Population-Based Surveillance, 2006-2011. Clin Infect Dis. 2015;61:584-592. [PMID: 25904365 DOI: 10.1093/cid/civ332] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 4.1] [Reference Citation Analysis]
14 Lawitz E, Sullivan G, Rodriguez-Torres M, Bennett M, Poordad F, Kapoor M, Badri P, Campbell A, Rodrigues L Jr, Hu Y, Pilot-Matias T, Vilchez RA. Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection. J Infect. 2015;70:197-205. [PMID: 25246359 DOI: 10.1016/j.jinf.2014.09.008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]